Kyoung-Ryul Lee, President & CEOSCL’s commitment to technological progress is exemplified by its AI-based prediction test service, the first of its kind among reference laboratories in South Korea. It leverages AI to estimate the risk of urinary tract infections based on urinalysis results. By providing healthcare professionals with predictive data, SCL enables quick, accurate diagnoses, ultimately reducing the time patients spend waiting for treatment. The integration of AI into diagnostic processes marks a significant leap forward, and SCL is actively developing further applications of AI, including rapid diagnostic tools powered by large language models and computer vision. These innovations are paving the way for a new era of clinical diagnostics that is faster, more accurate and more accessible.
“At SCL, we believe in pushing the boundaries of technology to empower clinicians with the tools they need to diagnose confidently and precisely,” says Kyoung-Ryul Lee, MD, PhD.
Another significant milestone of SCL is its collaboration with Philips to establish the first digital pathology system among reference laboratories in South Korea. This enhances diagnostic accuracy by structuring and standardizing pathologic diagnoses. By digitizing pathology workflows, it reduces the workload and streamlines the storage and retrieval of slides, improving access to past data and enabling more effective clinical decision-making. SCL’s digital pathology system lays the foundation for further transformative developments in AI-powered pathology and big data research in medical diagnostics.
Beyond technological innovation, SCL stands out for its unwavering commitment to quality and regulatory compliance. The company made history in South Korea by receiving accreditation from the College of American Pathologists, a distinction that underscores its dedication to maintaining the highest standards in clinical testing. In 2021, SCL also achieved ISO 15189 accreditation, affirming its adherence to internationally recognized standards for medical laboratories. These are just the beginning of SCL’s pursuit of excellence. In 2023, the company became the first clinical testing institution in Asia to receive the A2LA ISO 20387 certification for biobanks. This prestigious certification enhances SCL’s capabilities in supporting scientific and clinical research with high-quality biospecimens, ensuring that its storage processes meet global standards for accuracy and reliability.
-
At SCL, we believe in pushing the boundaries of technology to empower clinicians with the tools they need to diagnose confidently and precisely.
SCL’s commitment to global expansion reflects its growing influence as a leader in clinical testing. With a robust network of clinical laboratories across South Korea, the company has strategically extended its reach beyond national borders. In 2003, it launched MOBIO, a commercial laboratory and hospital in Mongolia, followed by the opening of K-lab in Jakarta, Indonesia in 2023. These international ventures highlight SCL’s dedication to delivering reliable, high-quality clinical testing services worldwide.
In addition to its core testing services, SCL offers a range of integrated services, including clinical trial support, biospecimen banking and Institutional Review Board oversight. The company has seven R&D centers and has developed an Integrated Research Administration System (CLRAS) to streamline the management of clinical trials, biospecimens and research projects. CLRAS enables efficient collaboration with domestic and international research institutions, contributing to the advancement of healthcare by supporting researchers in their pursuit of groundbreaking discoveries.
Through its dedication to innovation, quality and collaboration, SCL sets the standard for laboratory medicine in the APAC region and beyond. Its partnerships with leading institutions, such as the collaborative studies with Australia’s CSIRO on genetic mutations across ethnic groups, demonstrate SCL’s commitment to advancing precision medicine and personalized healthcare. By maintaining its focus on evidence-based medicine and leveraging the latest technologies, SCL is helping shape the future of healthcare, one test at a time.
Clinical Testing Services Info
Why is Seoul Clinical Laboratories recognized among leading Clinical Testing Services providers?
Seoul Clinical Laboratories (SCL) has established a strong reputation in Clinical Testing Services through more than four decades of experience in diagnostic medicine and reference laboratory operations. Founded in 1983, it has grown into one of Korea’s leading clinical laboratory institutions, supporting hospitals, clinics, and research organizations with high-volume diagnostic testing. Its recognition is reinforced by international accreditations such as CAP and ISO 15189, which validate its adherence to global laboratory quality and safety standards.
What differentiates SCL in clinical diagnostics and testing operations?
A defining strength of SCL within Clinical Testing Services is its integration of advanced diagnostic technologies with centralized laboratory systems. The company operates Korea’s first dedicated Central Laboratory (C-LAB) for clinical trials, enabling standardized testing across multi-center studies and reducing variability in results. This structure ensures consistency in sample handling, analysis, and reporting, which is critical for pharmaceutical research and regulatory submissions.
How does SCL support clinical trials and pharmaceutical research?
SCL plays a significant role in supporting drug development through its Clinical Testing Services by managing end-to-end clinical trial sample workflows. This includes specimen kit preparation, sample transport, laboratory analysis, and electronic data reporting compatible with clinical research systems. Its C-LAB model also enables centralized data management for global and multi-site trials, helping sponsors maintain consistency and improve statistical reliability across study phases.
What role does technology play in SCL’s testing services?
Technology is central to SCL’s Clinical Testing Services, particularly through the adoption of AI-driven diagnostics and digital pathology systems. The company has implemented AI-based predictive testing tools and partnered to develop digital pathology workflows that enhance diagnostic speed and accuracy. These innovations allow clinicians to interpret results more efficiently while improving decision-making in complex disease detection and monitoring.
How does SCL ensure quality and regulatory compliance in testing?
Quality assurance is deeply embedded in SCL’s Clinical Testing Services through strict adherence to global regulatory frameworks and accreditation standards. The laboratory operates under CAP certification and ISO 15189 compliance, ensuring standardized processes across all testing phases. Additional certifications and external quality assessment programs further strengthen its ability to deliver accurate, reproducible, and audit-ready diagnostic results for clinical and research applications.
Why is SCL relevant to modern healthcare and precision diagnostics?
SCL remains highly relevant in Clinical Testing Services due to growing demand for precision diagnostics, large-scale data integration, and AI-supported healthcare solutions. Its expansion into predictive testing, digital pathology, and global clinical trial support reflects a broader shift toward data-driven medicine. By combining traditional laboratory expertise with advanced digital systems, SCL supports faster, more precise, and more scalable diagnostic workflows that align with modern healthcare needs.
